This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Eiger BioPharmaceuticals Toekomstige groei

Future criteriumcontroles 0/6

Momenteel beschikken we niet over voldoende analisten om de groei en omzet voor Eiger BioPharmaceuticals te voorspellen.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Biotechs winstgroei	27.5%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	None
Laatst bijgewerkt	n/a

Recente toekomstige groei-updates

Recent updates

Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) 28% Dip In Price Shows Sentiment Is Matching Revenues

Apr 01

The Market Doesn't Like What It Sees From Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) Revenues Yet As Shares Tumble 26%

Jan 04

Analysts Have Just Cut Their Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Revenue Estimates By 22%

Dec 20

Analyst Forecasts For Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Are Surging Higher

Nov 09

Rock star Growth Puts Eiger BioPharmaceuticals (NASDAQ:EIGR) In A Position To Use Debt

Oct 06

In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat Eiger BioPharmaceuticals onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.

Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.

Winst- en omzetgroeiprognoses

OTCPK:EIGR.Q - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2023	16	-75	-75	-75	N/A
9/30/2023	15	-87	-83	-83	N/A
6/30/2023	15	-96	-89	-89	N/A
3/31/2023	15	-97	-89	-89	N/A
12/31/2022	13	-97	-83	-83	N/A
9/30/2022	14	-93	-78	-78	N/A
6/30/2022	13	-89	-76	-76	N/A
3/31/2022	11	-86	-75	-75	N/A
12/31/2021	12	-34	-71	-71	N/A
9/30/2021	9	-31	-70	-70	N/A
6/30/2021	6	-24	-65	-65	N/A
3/31/2021	4	-21	-60	-60	N/A
12/31/2020	N/A	-65	-63	-63	N/A
9/30/2020	N/A	-63	-63	-63	N/A
6/30/2020	N/A	-66	-64	-63	N/A
3/31/2020	N/A	-68	-63	-62	N/A
12/31/2019	N/A	-70	-64	-64	N/A
9/30/2019	N/A	-70	-61	-61	N/A
6/30/2019	N/A	-68	-60	-60	N/A
3/31/2019	N/A	-61	-53	-53	N/A
12/31/2018	N/A	-52	-43	-43	N/A
9/30/2018	N/A	-47	-41	-41	N/A
6/30/2018	N/A	-39	-35	-35	N/A
3/31/2018	N/A	-40	-36	-36	N/A
12/31/2017	N/A	-42	-38	-38	N/A
9/30/2017	N/A	-44	N/A	-39	N/A
6/30/2017	N/A	-47	N/A	-38	N/A
3/31/2017	N/A	-49	N/A	-45	N/A
12/31/2016	N/A	-47	N/A	-38	N/A
9/30/2016	N/A	-41	N/A	-30	N/A
6/30/2016	N/A	-33	N/A	-25	N/A
3/31/2016	N/A	-22	N/A	-12	N/A
12/31/2015	N/A	-13	N/A	-9	N/A
9/30/2015	N/A	-7	N/A	-6	N/A
12/31/2014	N/A	-2	N/A	-1	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er zijn onvoldoende gegevens om te bepalen of de verwachte winstgroei van EIGR.Q boven de spaarquote ( 2.5% ) ligt.

Winst versus markt: Er zijn onvoldoende gegevens om te bepalen of de winst van EIGR.Q naar verwachting sneller zal groeien dan de markt US

Hoge groeiwinsten: Er zijn onvoldoende gegevens om te bepalen of de winst van EIGR.Q naar verwachting de komende 3 jaar aanzienlijk zal groeien.

Omzet versus markt: Er zijn onvoldoende gegevens om te bepalen of de omzet van EIGR.Q naar verwachting sneller zal groeien dan de markt US.

Hoge groei-inkomsten: Er zijn onvoldoende gegevens om te bepalen of de omzet van EIGR.Q naar verwachting sneller zal groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van EIGR.Q naar verwachting over 3 jaar hoog zal zijn

This company is no longer active

Eiger BioPharmaceuticals Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased by 67% to US$30.00

No longer forecast to breakeven

Consensus EPS estimates upgraded to US$1.45 loss

No longer forecast to breakeven

Consensus EPS estimates upgraded to US$1.57 loss, revenue downgraded

Consensus EPS estimates upgraded to US$1.07 loss, revenue downgraded

Recent updates

Eiger BioPharmaceuticals, Inc. Went Out of Business

Motion for Asset Sale Approved for Eiger BioPharmaceuticals, Inc.

Motion for Asset Sale Filed by Eiger BioPharmaceuticals, Inc.

Spruce Biosciences, Inc. (NasdaqGS:SPRB) completed the acquisition of Substantially all of rights, title, interests, assets in Avexitide of Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $10 million.

Sentynl Therapeutics, Inc. acquired Global rights to Zokinvy Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $45.2 million.

Eiger BioPharmaceuticals, Inc.(NasdaqGM:EIGR) dropped from NASDAQ Composite Index

The Nasdaq Stock Market LLC Determines Eiger Biopharmaceuticals' Common Stock to be Delisted from Nasdaq

Motion for Asset Sale Filed by Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals, Inc. Filed for Bankruptcy

Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) 28% Dip In Price Shows Sentiment Is Matching Revenues

Eiger BioPharmaceuticals, Inc. Filed for Bankruptcy

Price target decreased by 67% to US$30.00

Ldon Mayer Iii Notifies Eiger BioPharmaceuticals, Inc. of His Resignation as the Chief Commercial Officer, Effective February 2, 2024

Eiger BioPharmaceuticals, Inc. and Partner, AnGes, Inc. Receive Approval for Zokinvy (Lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan

The Market Doesn't Like What It Sees From Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) Revenues Yet As Shares Tumble 26%

Moshe Arkin Sends a Letter to Eiger BioPharmaceuticals

Moshe Arkin Sends a Letter to Eiger BioPharmaceuticals

Eiger BioPharmaceuticals Receives Deficiency Letter from Nasdaq Regarding No Longer Satisfies the $10 Million Stockholders’ Equity Requirement for Continued Listing on The Nasdaq Global Market

New major risk - Negative shareholders equity

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Market cap size

Eiger BioPharmaceuticals, Inc. Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis Delta

No longer forecast to breakeven

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Eiger BioPharmaceuticals Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement Pursuant to Nasdaq Listing Rule 5450(a)(1)

New major risk - Share price stability

Consensus EPS estimates upgraded to US$1.45 loss

Eiger Biopharmaceuticals, Inc. Appoints David Apelian, as CEO

Eiger BioPharmaceuticals, Inc.(NasdaqGM:EIGR) dropped from Russell Small Cap Comp Value Index

No longer forecast to breakeven

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates upgraded to US$1.57 loss, revenue downgraded

Consensus EPS estimates upgraded to US$1.07 loss, revenue downgraded

No longer forecast to breakeven

Full year 2022 earnings: EPS and revenues miss analyst expectations

Eiger BioPharmaceuticals, Inc. Publishes Positive Phase 3 TOGETHER Results with Peginterferon Lambda in COVID-19

Independent Chairman recently bought US$72k worth of stock

Eiger BioPharmaceuticals, Inc. Announces Sriram Ryali to Resign as Chief Financial Officer, Effective January 20, 2023

Forecast to breakeven in 2025

Key Executive recently bought US$128k worth of stock

RM LAW Announces Class Action Lawsuit Against Eiger Biopharmaceuticals, Inc

Analysts Have Just Cut Their Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Revenue Estimates By 22%

Eiger BioPharmaceuticals, Inc. Announces CEO Changes

Price target decreased to US$9.25

Eiger BioPharmaceuticals, Inc. Announces Topline Primary Week 48 Data from Its Landmark Phase 3 D-LIVR study

Forecast to breakeven in 2024

Pomerantz Law Firm Announces the Filing of a Class Action Against Eiger BioPharmaceuticals, Inc

Analyst Forecasts For Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Are Surging Higher

Third quarter 2022 earnings: EPS misses analyst expectations

Eiger BioPharmaceuticals, Inc. Provides Update on Plans for Emergency Use Authorization Application Following FDA Feedback

Rock star Growth Puts Eiger BioPharmaceuticals (NASDAQ:EIGR) In A Position To Use Debt

Eiger sheds ~20% on abandonment of EUA request for COVID therapy

Eiger Biopharmaceuticals Provides Update on Status of Planned Peginterferon Lambda COVID-19 Emergency Use Authorization Application

Eiger falls 21% amid uncertainty over regulatory path for COVID-19 therapy

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Eiger BioPharmaceuticals: Undervalued Biotech With End Of 2022 Catalyst

Eiger Biopharmaceuticals Inc. Announces European Commission (Ec) Has Granted Marketing Authorization for Zokinvy® (Lonafarnib

European Commission approves Eiger BioPharmaceuticals' progeria therapy Zokinvy

Eiger BioPharmaceuticals, Inc. Appoints Lisa Kelly-Croswell to Board of Directors

Eiger BioPharmaceuticals, Inc. Announces Results from Multiple Presentations at the European Association for the Study of the Liver International Liver Congress 2022

Eiger Biopharmaceuticals, Inc. Announces New Data Supporting Broader Potential of Avexitide in Patients with Post-Bariatric Hypoglycemia and Hyperinsulinemic Hypoglycemia After Gastrointestinal Surgeries

Insufficient new directors

Eiger Biopharmaceuticals, Inc. Receives Positive Chmp Opinion for Zokinvy as A Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies

Consensus revenue estimates fall by 22%

Insufficient new directors

Price target increased to US$32.00

Eiger BioPharmaceuticals, Inc. Announces Publication of Positive Phase 2 Results of Avexitide in Children with Congenital Hyperinsulinism and Initiation of Phase 3 Program